On July 11, 2025, Amit Kumar, the CEO of Anixa Biosciences Inc (ANIX, Financial), purchased 5,000 shares of the company, according to a SEC Filing. This transaction increases the insider's total ownership to 574,925 shares.
Anixa Biosciences Inc is a biotechnology company focused on harnessing the body's immune system in the fight against cancer and infectious diseases. The company is involved in developing innovative therapies and vaccines.
The recent purchase by Amit Kumar is part of a broader trend of insider buying at Anixa Biosciences Inc. Over the past year, the insider has acquired a total of 58,000 shares and has not sold any shares. This activity is consistent with the overall insider transaction history for the company, which shows 12 insider buys and no insider sells over the same period.
Shares of Anixa Biosciences Inc were trading at $3.15 each on the day of the purchase, giving the stock a market cap of $101.349 million. Investors often view insider buying as a positive signal, indicating confidence in the company's future prospects.
For more information on the company's valuation metrics, such as the GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can refer to the respective links.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
